The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

RBC expressed particular enthusiasm for ACP-204, described as a next-generation version of Nuplazid targeting more expansive neuropsychiatric disorders, with an estimated $940 million market ...

In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics ...

RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and increased its price target from $55 to $57 on June 13.

RBC indices such as mean corpuscular volume, mean corpuscular hemoglobin concentration, and red cell distribution width are laboratory parameters that are frequently overlooked in clinical practice.

People will frown at you; they will mock you and will often tell you go to bed earlier and not sleep on the job.

In this article, we identify the top 10 most impactful articles for pediatric hospital medicine in 2025, as presented at the ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

Shares of Regencell Bioscience (NASDAQ:RGC) gained 49,637% in the past six months despite record losses since going public in 2021. The Chinese medicine company, with shareholders like Digital Mobile ...